SITC2022 | Blood Cancers Today

SITC2022

Cecilia BrownMyeloma | February 7, 2023

AgenT-797 is a scalable, off-the-shelf therapy that retains potent cytotoxicity after cryopreservation.

Cecilia BrownIndolent B-Cell Lymphoma | December 22, 2022

Patients with LBCL received prophylactic anakinra to reduce the risk of cytokine release syndrome following CAR-T.

Leah SherwoodHodgkin Lymphoma | December 22, 2022

Penpulimab demonstrated a good safety profile in patients with relapsed/refractory classical Hodgkin lymphoma.

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer